全文获取类型
收费全文 | 163360篇 |
免费 | 32941篇 |
国内免费 | 2420篇 |
专业分类
耳鼻咽喉 | 5334篇 |
儿科学 | 5994篇 |
妇产科学 | 2924篇 |
基础医学 | 5274篇 |
口腔科学 | 1730篇 |
临床医学 | 27399篇 |
内科学 | 50188篇 |
皮肤病学 | 7631篇 |
神经病学 | 15816篇 |
特种医学 | 6938篇 |
外科学 | 42727篇 |
综合类 | 282篇 |
现状与发展 | 72篇 |
一般理论 | 3篇 |
预防医学 | 8194篇 |
眼科学 | 3740篇 |
药学 | 2189篇 |
中国医学 | 32篇 |
肿瘤学 | 12254篇 |
出版年
2024年 | 519篇 |
2023年 | 4851篇 |
2022年 | 1313篇 |
2021年 | 3387篇 |
2020年 | 6185篇 |
2019年 | 2330篇 |
2018年 | 7649篇 |
2017年 | 7566篇 |
2016年 | 8665篇 |
2015年 | 8694篇 |
2014年 | 15827篇 |
2013年 | 16098篇 |
2012年 | 6097篇 |
2011年 | 6186篇 |
2010年 | 10721篇 |
2009年 | 14505篇 |
2008年 | 6204篇 |
2007年 | 4455篇 |
2006年 | 6917篇 |
2005年 | 4212篇 |
2004年 | 3509篇 |
2003年 | 2470篇 |
2002年 | 2601篇 |
2001年 | 4234篇 |
2000年 | 3427篇 |
1999年 | 3590篇 |
1998年 | 3761篇 |
1997年 | 3552篇 |
1996年 | 3448篇 |
1995年 | 3269篇 |
1994年 | 1991篇 |
1993年 | 1626篇 |
1992年 | 1627篇 |
1991年 | 1632篇 |
1990年 | 1292篇 |
1989年 | 1396篇 |
1988年 | 1223篇 |
1987年 | 1052篇 |
1986年 | 1103篇 |
1985年 | 903篇 |
1984年 | 704篇 |
1983年 | 654篇 |
1982年 | 597篇 |
1981年 | 477篇 |
1979年 | 499篇 |
1978年 | 453篇 |
1977年 | 502篇 |
1975年 | 432篇 |
1972年 | 464篇 |
1970年 | 429篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
32.
33.
34.
Rafiye Ciftciler Haluk Demiroglu Yahya Buyukasık Elifcan Aladag Salih Aksu Ibrahim C. Haznedaroglu Nilgun Sayınalp Osman Ozcebe Umit Yavuz Malkan Hakan Goker 《Clinical Lymphoma, Myeloma & Leukemia》2019,19(3):177-182
Background
Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML.Patients and Methods
We retrospectively analyzed the clinical outcome of 91 patients who were diagnosed with treatment-refractory AML at Hacettepe University Hospital between January 2002 and June 2018. Patients' disease status included refractory AML, defined as failure to respond to standard induction chemotherapy and relapse within 6 months after first complete remission.Results
The median follow-up was 12 months (range, 0.5-184 months) for the entire group. Kaplan-Meier estimates of the 3-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 67% and 12%, respectively. Additionally, the Kaplan-Meier estimates of 5-year overall survival for patients who underwent allo-HSCT and patients who received only salvage chemotherapy were 44% and 4%, respectively (P < .001). Complete remission was obtained in 25 patients (83.3%) who underwent allo-HSCT; however, the disease of only 3 patients (3.8%) exhibited complete response after salvage chemotherapy.Conclusion
Allo-HSCT is still the best-known treatment option with curative potential in patients with treatment-refractory AML. Therefore, all efforts should be made in an attempt to find a suitable matched donor in order to perform allo-HSCT. 相似文献35.
Jamaal L. Benjamin MD PhD Rebecca Dennis DO Stacy White Jr MD David Munson MD Sudha A. Anupindi MD Maciej Piskunowicz MD Kassa Darge MD PhD Ami Gokli MD Misun Hwang MD 《Journal of ultrasound in medicine》2020,39(5):1031-1036
Bowel diseases of prematurity, including necrotizing enterocolitis, are dreaded ailments of neonates. Early diagnosis is difficult, with clinical and radiographic findings often inconclusive. We present a novel use of contrast-enhanced ultrasound in detection of pediatric bowel disease. Early identification of compromised blood flow or an at-risk bowel can be quantitatively detected and monitored. This ability has implications for guidance of emerging therapies, allowing targeting of inflammation. These findings represent an advancement in detection of bowel disease in neonates. 相似文献
36.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
37.
38.
39.
40.